Thioredoxin-1 Activation by Pterostilbene Protects Against Doxorubicin-Induced Hepatotoxicity via Inhibiting the NLRP3 Inflammasome

• Egile Nagusiak: Shiqing Tan (Egilea), Jie Bai (Egilea), Mingxi Xu (Egilea), Longying Zhang (Egilea), Ying Wang (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Doxorubicin (DOX) has been widely used in cancer treatment. However, DOX can cause a range of significant side effects, of which hepatotoxicity is a common one, and therefore limits its clinical use. Pterostilbene (PTS) has been shown to exhibit anti-oxidant and anti-inflammatory effects...